Workflow
TELA Bio(TELA) - 2025 Q3 - Quarterly Results
TELA BioTELA Bio(US:TELA)2025-11-13 21:08

Financial Performance - Revenue for Q3 2025 was $20.7 million, a 9% increase compared to Q3 2024[3] - Gross profit was $14.0 million, representing 67.5% of revenue, compared to 67.8% in Q3 2024[4] - Operating expenses decreased to $21.5 million from $22.2 million in Q3 2024, primarily due to lower compensation and benefits[6] - Loss from operations improved to $7.6 million in Q3 2025, compared to a loss of $9.4 million in Q3 2024[7] - Net loss for Q3 2025 was $8.6 million, down from $10.4 million in Q3 2024[8] Cash and Financing - Cash and cash equivalents totaled $29.7 million as of September 30, 2025[8] - The company secured a credit facility of up to $70.0 million from Perceptive Advisors, with an initial loan of $60.0 million[10] Growth and Strategy - Full year 2025 revenue guidance revised to project at least 16% growth over 2024[9] - The company achieved its 2025 hiring target in the U.S. sales organization[5] - The addition of new customers and growing international sales contributed to revenue growth[3]